DK169521B1 - 3-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne - Google Patents

3-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne Download PDF

Info

Publication number: DK169521B1
Authority: DK; Denmark
Prior art keywords: methyl; general formula; compound; hydrogen; tetrahydro
Prior art date: 1984-01-25

Application number

DK035785A

Other languages

Danish (da)

English (en)

Other versions

DK35785D0 (da

DK35785A (da

Inventor

Ian Harold Coates

James Angus Bell

David Cedric Humber

Georges Blanch Ewan

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-01-25

Filing date

1985-01-25

Publication date

1994-11-21

1984-01-25 Priority claimed from GB848401888A external-priority patent/GB8401888D0/en

1984-10-15 Priority claimed from GB848425959A external-priority patent/GB8425959D0/en

1985-01-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1985-01-25 Publication of DK35785D0 publication Critical patent/DK35785D0/da

1985-07-26 Publication of DK35785A publication Critical patent/DK35785A/da

1994-11-21 Application granted granted Critical

1994-11-21 Publication of DK169521B1 publication Critical patent/DK169521B1/da

Links

150000001875 compounds Chemical class 0.000 title claims description 142
238000002360 preparation method Methods 0.000 title claims description 28
238000000034 method Methods 0.000 title claims description 27
230000008569 process Effects 0.000 title claims description 17
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
ZHIDLFGPDBGBLX-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-2,3,4,4a-tetrahydrocarbazol-1-one Chemical class C1C(C2=CC=CC=C2N=2)C=2C(=O)CC1CC1=NC=CN1 ZHIDLFGPDBGBLX-UHFFFAOYSA-N 0.000 title claims description 4
150000003839 salts Chemical class 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 49
-1 prop-2-enyl Chemical group 0.000 claims description 34
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
229910052739 hydrogen Inorganic materials 0.000 claims description 31
239000001257 hydrogen Substances 0.000 claims description 31
239000004480 active ingredient Substances 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 20
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
125000003342 alkenyl group Chemical group 0.000 claims description 15
239000012453 solvate Substances 0.000 claims description 15
150000002431 hydrogen Chemical group 0.000 claims description 12
239000012458 free base Substances 0.000 claims description 11
239000000843 powder Substances 0.000 claims description 9
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical group CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
238000005804 alkylation reaction Methods 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
238000005984 hydrogenation reaction Methods 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
230000029936 alkylation Effects 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
FSJSRSHEOFVRHM-UHFFFAOYSA-N 1-methyl-3-[(2-methylimidazol-1-yl)methyl]carbazol-4-one Chemical compound CC1=NC=CN1CC(C1=O)=CC(C)=C2C1=C1C=CC=CC1=N2 FSJSRSHEOFVRHM-UHFFFAOYSA-N 0.000 claims description 2
MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
239000012530 fluid Substances 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
DNEFVEWFSTYRNM-UHFFFAOYSA-N 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-1,2,3,4-tetrahydrocarbazole Chemical group CC1=NC=CN1CC1CC(C=2C(=CC=CC=2)N2C)=C2CC1 DNEFVEWFSTYRNM-UHFFFAOYSA-N 0.000 claims 1
WRZJOBREMUDSSV-UHFFFAOYSA-N 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;hydrate;hydrochloride Chemical compound O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 WRZJOBREMUDSSV-UHFFFAOYSA-N 0.000 claims 1
239000002245 particle Substances 0.000 claims 1
238000007789 sealing Methods 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 128
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
239000000243 solution Substances 0.000 description 66
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
235000019441 ethanol Nutrition 0.000 description 43
239000007787 solid Substances 0.000 description 42
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
239000000047 product Substances 0.000 description 28
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
238000004458 analytical method Methods 0.000 description 24
239000000725 suspension Substances 0.000 description 23
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 23
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 20
229910052757 nitrogen Inorganic materials 0.000 description 20
239000003921 oil Substances 0.000 description 19
235000019198 oils Nutrition 0.000 description 19
239000003826 tablet Substances 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 17
229910000041 hydrogen chloride Inorganic materials 0.000 description 17
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
239000002904 solvent Substances 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
238000002844 melting Methods 0.000 description 12
230000008018 melting Effects 0.000 description 12
238000010992 reflux Methods 0.000 description 12
229910021529 ammonia Inorganic materials 0.000 description 11
238000004809 thin layer chromatography Methods 0.000 description 11
239000002253 acid Substances 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000000284 extract Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
230000001537 neural effect Effects 0.000 description 10
239000002585 base Substances 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 8
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
239000000443 aerosol Substances 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
239000011976 maleic acid Substances 0.000 description 8
238000011282 treatment Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000004440 column chromatography Methods 0.000 description 7
238000007796 conventional method Methods 0.000 description 7
239000007800 oxidant agent Substances 0.000 description 7
229910000029 sodium carbonate Inorganic materials 0.000 description 7
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
208000019695 Migraine disease Diseases 0.000 description 6
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000004423 acyloxy group Chemical group 0.000 description 6
150000001408 amides Chemical class 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
229910052736 halogen Inorganic materials 0.000 description 6
150000002367 halogens Chemical class 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
206010027599 migraine Diseases 0.000 description 6
229910000104 sodium hydride Inorganic materials 0.000 description 6
239000012312 sodium hydride Substances 0.000 description 6
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000006260 foam Substances 0.000 description 5
150000004677 hydrates Chemical class 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
150000002688 maleic acid derivatives Chemical class 0.000 description 5
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
ZBFZXENHYIJZGA-UHFFFAOYSA-N 2,3,4,4a-tetrahydrocarbazol-1-one Chemical compound C1=CC=C2C3CCCC(=O)C3=NC2=C1 ZBFZXENHYIJZGA-UHFFFAOYSA-N 0.000 description 4
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000012267 brine Substances 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000007429 general method Methods 0.000 description 4
230000008570 general process Effects 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
230000001590 oxidative effect Effects 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
201000000980 schizophrenia Diseases 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000008107 starch Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
239000004338 Dichlorodifluoromethane Substances 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000028017 Psychotic disease Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
AMLYRCOEFHJSFS-UHFFFAOYSA-N carbazol-1-one Chemical group C1=CC=C2C3=CC=CC(=O)C3=NC2=C1 AMLYRCOEFHJSFS-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
235000019404 dichlorodifluoromethane Nutrition 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
CQQJSOXDEFZGFG-UHFFFAOYSA-N imidazo[4,5-d]imidazole Chemical compound C1=NC2=NC=NC2=N1 CQQJSOXDEFZGFG-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
238000003825 pressing Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
239000008354 sodium chloride injection Substances 0.000 description 3
229940029284 trichlorofluoromethane Drugs 0.000 description 3
238000000825 ultraviolet detection Methods 0.000 description 3
210000001186 vagus nerve Anatomy 0.000 description 3
FOTRUJUPLHRVNU-QNBGGDODSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid;hydrate Chemical compound O.C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 FOTRUJUPLHRVNU-QNBGGDODSA-N 0.000 description 2
FHGHPOYZHSPOOI-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(2-methylimidazol-1-yl)methyl]-9-phenyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C=3C=CC=CC=3)=C2CC1 FHGHPOYZHSPOOI-BTJKTKAUSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
ZOHGNMNHFUUYCZ-UHFFFAOYSA-N 3-(chloromethyl)-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)C(CCl)CC2 ZOHGNMNHFUUYCZ-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
VRSLTNZJOUZKLX-UHFFFAOYSA-N Ondansetron hydrochloride Chemical compound O.O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 VRSLTNZJOUZKLX-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
150000008041 alkali metal carbonates Chemical class 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000036528 appetite Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 2
229940117975 chromium trioxide Drugs 0.000 description 2
WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 2
GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
230000035418 detection of UV Effects 0.000 description 2
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000004744 fabric Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000015654 memory Effects 0.000 description 2
230000036651 mood Effects 0.000 description 2
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000010004 neural pathway Effects 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008213 purified water Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
150000004053 quinones Chemical class 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000011514 reflex Effects 0.000 description 2
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000006190 sub-lingual tablet Substances 0.000 description 2
229940098466 sublingual tablet Drugs 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
XVNKNFCMXHXIPO-GZJHNZOKSA-N (2R,3R)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid hydrate Chemical compound O.C1(=CC=C(C=C1)C(=O)[C@@]([C@@](C(=O)O)(O)C(=O)C1=CC=C(C=C1)C)(O)C(=O)O)C XVNKNFCMXHXIPO-GZJHNZOKSA-N 0.000 description 1
NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 description 1
DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
DBWOOUPJVRZEPP-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(2-methylimidazol-1-yl)methyl]-9-prop-2-enyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2CC=C)=C2CC1 DBWOOUPJVRZEPP-BTJKTKAUSA-N 0.000 description 1
WYHFUCMVSCUJGJ-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(2-methylimidazol-1-yl)methyl]-9-propyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.O=C1C=2C3=CC=CC=C3N(CCC)C=2CCC1CN1C=CN=C1C WYHFUCMVSCUJGJ-BTJKTKAUSA-N 0.000 description 1
YVNIWAADRJOYTI-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-cyclopentyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C3CCCC3)=C2CC1 YVNIWAADRJOYTI-BTJKTKAUSA-N 0.000 description 1
DSXKDTZEIWTHRO-UHFFFAOYSA-N 1,2,3,9-tetrahydrocarbazol-4-one Chemical class N1C2=CC=CC=C2C2=C1CCCC2=O DSXKDTZEIWTHRO-UHFFFAOYSA-N 0.000 description 1
QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
229940005561 1,4-benzoquinone Drugs 0.000 description 1
NUIOGJWGSZFUAG-UHFFFAOYSA-N 1-[(2-methylimidazol-1-yl)methyl]carbazol-4-one Chemical compound CC1=NC=CN1CC(C=CC1=O)=C2C1=C1C=CC=CC1=N2 NUIOGJWGSZFUAG-UHFFFAOYSA-N 0.000 description 1
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
MKBBSFGKFMQPPC-UHFFFAOYSA-N 2-propyl-1h-imidazole Chemical compound CCCC1=NC=CN1 MKBBSFGKFMQPPC-UHFFFAOYSA-N 0.000 description 1
KLUNAVKHVFZQKF-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound C1CC=2NC3=CC=CC=C3C=2C(=O)C1CN1C=CN=C1 KLUNAVKHVFZQKF-UHFFFAOYSA-N 0.000 description 1
UQCPFXZJDPUQJW-UHFFFAOYSA-N 3-[(2-methylimidazol-1-yl)methyl]-9-propan-2-yl-2,3-dihydro-1h-carbazol-4-one;hydrochloride Chemical compound Cl.O=C1C=2C3=CC=CC=C3N(C(C)C)C=2CCC1CN1C=CN=C1C UQCPFXZJDPUQJW-UHFFFAOYSA-N 0.000 description 1
UEWOZJZAMBVKAE-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound N1C2=CC=CC=C2C2=C1CCC(CN(C)C)C2=O UEWOZJZAMBVKAE-UHFFFAOYSA-N 0.000 description 1
BSGMMRNLRWFVHL-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)C(CN(C)C)CC2 BSGMMRNLRWFVHL-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
QMAAAVCBEQIZHZ-UHFFFAOYSA-N 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-1,2,3,4-tetrahydrocarbazol-4-ol Chemical compound CC1=NC=CN1CC1C(O)C(C=2C(=CC=CC=2)N2C)=C2CC1 QMAAAVCBEQIZHZ-UHFFFAOYSA-N 0.000 description 1
RXQNYZZEDXNKDG-UHFFFAOYSA-N 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;phosphoric acid Chemical compound OP(O)(O)=O.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 RXQNYZZEDXNKDG-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
150000001450 anions Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000001062 anti-nausea Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WYXPBFJNQZWFCO-UHFFFAOYSA-N carbazol-4-one;hydrochloride Chemical compound Cl.C1=CC=CC2=C3C(=O)C=CC=C3N=C21 WYXPBFJNQZWFCO-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000005059 dormancy Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002815 homogeneous catalyst Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229910000039 hydrogen halide Inorganic materials 0.000 description 1
239000012433 hydrogen halide Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
229960002523 mercuric chloride Drugs 0.000 description 1
LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
HHVIBTZHLRERCL-UHFFFAOYSA-N methylsulphonylmethane Natural products CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
229910003445 palladium oxide Inorganic materials 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000010970 precious metal Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
230000037047 psychomotor activity Effects 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
229960004016 sucrose syrup Drugs 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
150000003461 sulfonyl halides Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
OKKJLVBELUTLKV-FIBGUPNXSA-N trideuteriomethanol Chemical compound [2H]C([2H])([2H])O OKKJLVBELUTLKV-FIBGUPNXSA-N 0.000 description 1
MDDPTCUZZASZIQ-UHFFFAOYSA-N tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] MDDPTCUZZASZIQ-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK035785A 1984-01-25 1985-01-25 3-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne DK169521B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8401888		1984-01-25
GB848401888A GB8401888D0 (en)	1984-01-25	1984-01-25	Heterocyclic compounds
GB8425959		1984-10-15
GB848425959A GB8425959D0 (en)	1984-10-15	1984-10-15	Heterocyclic compounds

Publications (3)

Publication Number	Publication Date
DK35785D0 DK35785D0 (da)	1985-01-25
DK35785A DK35785A (da)	1985-07-26
DK169521B1 true DK169521B1 (da)	1994-11-21

Family

ID=26287221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK035785A DK169521B1 (da)	1984-01-25	1985-01-25	3-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne

Country Status (29)

Country	Link
KR (1)	KR920003064B1 (fr)
AT (1)	AT392276B (fr)
AU (1)	AU579132B2 (fr)
BE (1)	BE901576A (fr)
CA (1)	CA1252793A (fr)
CH (1)	CH664152A5 (fr)
CY (1)	CY1479A (fr)
CZ (1)	CZ404391A3 (fr)
DE (2)	DE3502508A1 (fr)
DK (1)	DK169521B1 (fr)
ES (3)	ES8609309A1 (fr)
FI (1)	FI84349C (fr)
FR (1)	FR2561244B1 (fr)
GB (1)	GB2153821B (fr)
GR (1)	GR850219B (fr)
HK (1)	HK33189A (fr)
HU (1)	HU193592B (fr)
IE (1)	IE57809B1 (fr)
IL (1)	IL74165A (fr)
IT (1)	IT1182150B (fr)
LU (2)	LU85743A1 (fr)
NL (2)	NL190373C (fr)
NO (2)	NO164025C (fr)
NZ (1)	NZ210940A (fr)
PH (1)	PH22672A (fr)
PT (1)	PT79890B (fr)
SE (1)	SE460359B (fr)
SG (1)	SG7089G (fr)
SK (1)	SK404391A3 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4695578A (en) *	1984-01-25	1987-09-22	Glaxo Group Limited	1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0191562B1 (fr) *	1985-01-23	1991-07-10	Glaxo Group Limited	Dérivés de tétrahydrocarbazolones
EP0405617A3 (en) *	1985-03-14	1992-11-25	Beecham Group P.L.C.	Medicaments for the treatment of anxiety
GB8516083D0 (en) *	1985-06-25	1985-07-31	Glaxo Group Ltd	Heterocyclic compounds
US5578628A (en) *	1985-06-25	1996-11-26	Glaxo Group Limited	Medicaments for the treatment of nausea and vomiting
GB8518745D0 (en)	1985-07-24	1985-08-29	Glaxo Group Ltd	Heterocyclic compounds
US5204356A (en) *	1985-07-24	1993-04-20	Glaxo Group Limited	Treatment of anxiety
GB8518743D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Heterocyclic compounds
GB8518741D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Process
GB8518742D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Process
GB8518658D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Medicaments
GB8617994D0 (en) *	1986-07-23	1986-08-28	Glaxo Group Ltd	Heterocyclic compounds
HU895334D0 (en) *	1986-07-30	1990-01-28	Sandoz Ag	Process for the preparation of nasal pharmaceutical compositions
AT396870B (de) *	1986-08-07	1993-12-27	Sandoz Ag	Verfahren zur herstellung einer galenischen formulierung zur nasalen verabreichung von serotoninantagonisten
GB8623819D0 (en) *	1986-10-03	1986-11-05	Glaxo Group Ltd	Heterocyclic compounds
EP0279114B2 (fr) *	1986-11-21	1995-08-23	Glaxo Group Limited	Médicaments pour le traitement ou la prévention du syndrome associé à un état de manque
GB8627909D0 (en) *	1986-11-21	1986-12-31	Glaxo Group Ltd	Medicaments
GB8628475D0 (en) *	1986-11-28	1987-01-07	Glaxo Group Ltd	Medicaments
US5202343A (en) *	1986-11-28	1993-04-13	Glaxo Group Limited	Tricyclic ketones useful as HT3 -receptor antagonists
GR871809B (en) *	1986-11-28	1988-03-07	Glaxo Group Ltd	Process for the preparation of tricyclic ketones
GB8812002D0 (en) *	1988-05-20	1988-06-22	Glaxo Group Ltd	Chemical compounds
US5190954A (en) *	1986-12-17	1993-03-02	Glaxo Group Limited	Methods for the treatment of cognitive disorders
GB8630079D0 (en) *	1986-12-17	1987-01-28	Glaxo Group Ltd	Medicaments
GB8630071D0 (en) *	1986-12-17	1987-01-28	Glaxo Group Ltd	Medicaments
EP0275668B1 (fr) *	1986-12-17	1992-09-30	Glaxo Group Limited	Emploi de dérivés de cétone pour le traitement de troubles de la démence
US4973594A (en) *	1986-12-17	1990-11-27	Glaxo Group Limited	Medicaments
US5200414A (en) *	1986-12-17	1993-04-06	Glaxo Group Limited	Methods for the treatment of cognitive disorders
EP0291172B1 (fr) *	1987-04-14	1992-11-19	Glaxo Group Limited	Dérivés de cétone
DE3874229T2 (de) *	1987-06-16	1993-03-25	British Tech Group	Verwendung von dioxopiperidin-derivaten zur herstellung eines topischen praeparates als analgetika.
DE3822792C2 (de) *	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten
GB8723157D0 (en) *	1987-10-02	1987-11-04	Beecham Group Plc	Compounds
EP0317088A1 (fr) *	1987-10-22	1989-05-24	Glaxo Group Limited	Dérivés cétoniques
CA1304082C (fr) *	1987-10-22	1992-06-23	Tetsuya Tahara	Composes de la benzoxazine et leurs utilisations pharmaceutiques
US5225431A (en) *	1987-10-23	1993-07-06	Burroughs Wellcome Co.	Therapeutic substituted indole compounds and compositions thereof
GB8805269D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
US5116984A (en) *	1988-04-07	1992-05-26	Glaxo Group Limited	Imidazole derivatives
DK185489A (da) *	1988-04-22	1989-10-23	Duphar Int Res	Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US4985422A (en) *	1988-04-27	1991-01-15	Glaxo Group Limited	Lactam derivatives
GB8812636D0 (en) *	1988-05-27	1988-06-29	Glaxo Group Ltd	Chemical compounds
US5173493A (en) *	1988-09-27	1992-12-22	Fujisawa Pharmaceutical Company, Ltd.	Pyridoindole derivatives and processes for preparation thereof
US5290785A (en) *	1988-09-27	1994-03-01	Fujisawa Pharmaceutical Co., Ltd.	Therapeutic agent for ischemic diseases
AU627221B2 (en) *	1988-09-27	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Pyridoindole derivatives and processes for preparation thereof
FR2639944B1 (fr) *	1988-12-06	1991-01-18	Adir	Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2004911A1 (fr) *	1988-12-22	1990-06-22	Mitsuaki Ohta	Derives de 4,5,6,7-tetrahydrobenzimidazole
US5223625A (en) *	1988-12-22	1993-06-29	Duphar International Research B.V.	Annelated indolo [3,2,-C]lactams
EP0377238A1 (fr) *	1988-12-22	1990-07-11	Duphar International Research B.V	Indolo(3,2-c)-lactames annelés
CA2012092A1 (fr) *	1989-03-13	1990-09-13	Tadao Okegawa	Inhibiteur des recepteurs 5-ht3
WO1990012569A1 (fr) *	1989-04-21	1990-11-01	Sandoz Ag	Application therapeutique d'antagonistes du recepteur 5-ht¿3?
GB8914804D0 (en) *	1989-06-28	1989-08-16	Glaxo Group Ltd	Process
GB8917557D0 (en) *	1989-08-01	1989-09-13	Glaxo Group Ltd	Medicaments
US5276050A (en) *	1989-08-01	1994-01-04	Glaxo Group Limited	Medicaments
US5126343A (en) *	1989-09-11	1992-06-30	G. D. Searle & Co.	N-azabicyclo [3.3.0]octane amides of aromatic acids
GB2236751B (en)	1989-10-14	1993-04-28	Wyeth John & Brother Ltd	Heterocyclic compounds
GB8928837D0 (en) *	1989-12-21	1990-02-28	Beecham Group Plc	Pharmaceuticals
US5187166A (en) *	1990-07-31	1993-02-16	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives and their use as antiemetics
EP0591434A4 (en) *	1991-06-26	1994-09-14	Sepracor Inc	Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JPH05310732A (ja) *	1992-03-12	1993-11-22	Mitsubishi Kasei Corp	シンノリン−３−カルボン酸誘導体
ES2043535B1 (es) *	1992-03-13	1994-08-01	Vita Invest Sa	Procedimiento para la obtencion de la 1,2,3,9-tetrahidro-9-metil-3-(2-metil-1h-imidazol-1-il)metil*-4h-carbazol-4-ona.
HU212934B (en)	1992-10-14	1996-12-30	Richter Gedeon Vegyeszet	Process for producing novel alkoxalylated carbazolone derivatives
CA2106642C (fr) *	1992-10-14	2005-08-16	Peter Bod	Derives de carbazolone et procede d'obtention
CN1118990A (zh) *	1993-03-08	1996-03-20	藤泽药品工业株式会社	治疗或预防脑血管疾病药物
GB9310756D0 (en) *	1993-05-25	1993-07-14	Glaxo Lab Sa	Compositions
GB2325409B (en) *	1994-06-28	1999-02-10	Kenneth Francis Prendergast	Pharmaceutical use of ondansetron/cyclodextrin complexes
GB9423588D0 (en) *	1994-11-22	1995-01-11	Glaxo Wellcome Inc	Compositions
AU702594B2 (en) *	1995-10-13	1999-02-25	Duphar International Research B.V.	Process for the preparation of enantiomerically pure imidazolyl compounds
US6365743B1 (en)	1995-10-13	2002-04-02	Duphar International Research B.V.	Process for the preparation of enantiomerically pure imidazolyl compounds
US5969137A (en) *	1996-09-19	1999-10-19	Virginia Commonwealth University	Benzylamidine derivatives with serotonin receptor binding activity
AU779696B2 (en)	1999-03-01	2005-02-10	Sepracor, Inc.	Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
EP1207160A1 (fr) *	2000-11-20	2002-05-22	Hanmi Pharm. Co., Ltd.	Procédé de préparation de la 1,2,3,9-tétrahydro-9-méthyl-3-((2-méthyl-1H-imidazol-1-yl)-méthyl)-4H-carbazol-4-one
RU2207340C2 (ru) *	2001-08-10	2003-06-27	Ципла Лтд.	Способ получения 1,2,3,9-тетрагидро-9-метил-3-[(2-метил-1н-имидазол-1-ил)метил]-4н-карбазол -4-она или его фармацевтически приемлемых солей
WO2003093281A1 (fr)	2002-04-29	2003-11-13	Biogal Gyogyszergyar Rt.	Methode de preparation de 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one
FI6164U1 (fi) *	2003-01-09	2004-03-15	Synthon Bv	Ondansetronmuotoja
GB2398071B (en) *	2003-01-24	2006-06-07	Synthon Bv	Process for making ondansetron and intermediate thereof
ES2238001B1 (es) *	2004-01-21	2006-11-01	Vita Cientifica, S.L.	Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
CA2565854A1 (fr)	2004-05-07	2005-11-17	Taro Pharmaceutical Industries Ltd.	Procede de preparation de chlorhydrate dihydrate d'ondansetron ayant une granulometrie definie
WO2007004041A2 (fr) *	2005-07-05	2007-01-11	Orchid Research Laboratories Limited	Nouveaux composes ainsi qu'utilisation pharmaceutique de ceux-ci
PL2432467T3 (pl)	2009-05-20	2018-07-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Zastosowanie antagonistów receptora 5-ht3 serotoniny w leczeniu zaburzeń przedsionkowych ze zmianami chorobowymi
EP2253316B1 (fr)	2009-05-20	2013-08-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonistes du récepteur 5-HT3 de la sérotonine pour une utilisation dans le traitement ou la prévention d'une pathologie de l'oreille interne avec déficits vestibulaires
CN115611864A (zh) *	2022-11-01	2023-01-17	常州兰陵制药有限公司	一种昂丹司琼类化合物及其制备方法与应用
GB202301322D0 (en)	2023-01-30	2023-03-15	Therakind Ltd	Antiemetic pharmaceutical compositions for nasal delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3740404A (en) *	1969-05-09	1973-06-19	American Cyanamid Co	Piperidinomethylenedihydrocarbazolones
US3634420A (en) *	1969-05-09	1972-01-11	American Cyanamid Co	3(morpholinomethyl)-2 3-dihydro-carbazol-4(1h)-ones
EP0191562B1 (fr) *	1985-01-23	1991-07-10	Glaxo Group Limited	Dérivés de tétrahydrocarbazolones

1985
- 1985-01-25 AT AT204/85A patent/AT392276B/de not_active IP Right Cessation
- 1985-01-25 DK DK035785A patent/DK169521B1/da not_active IP Right Cessation
- 1985-01-25 KR KR1019850000454A patent/KR920003064B1/ko not_active Expired
- 1985-01-25 DE DE19853502508 patent/DE3502508A1/de active Granted
- 1985-01-25 BE BE0/214394A patent/BE901576A/fr not_active IP Right Cessation
- 1985-01-25 NL NLAANVRAGE8500202,A patent/NL190373C/xx not_active IP Right Cessation
- 1985-01-25 LU LU85743A patent/LU85743A1/fr active Protection Beyond IP Right Term
- 1985-01-25 GR GR850219A patent/GR850219B/el active IP Right Revival
- 1985-01-25 FR FR8501056A patent/FR2561244B1/fr not_active Expired
- 1985-01-25 PH PH31770A patent/PH22672A/en unknown
- 1985-01-25 HU HU85296A patent/HU193592B/hu unknown
- 1985-01-25 CH CH346/85A patent/CH664152A5/fr not_active IP Right Cessation
- 1985-01-25 NZ NZ210940A patent/NZ210940A/xx unknown
- 1985-01-25 ES ES539852A patent/ES8609309A1/es not_active Expired
- 1985-01-25 IE IE187/85A patent/IE57809B1/en not_active IP Right Cessation
- 1985-01-25 IT IT47600/85A patent/IT1182150B/it active Protection Beyond IP Right Term
- 1985-01-25 SE SE8500368A patent/SE460359B/sv not_active IP Right Cessation
- 1985-01-25 FI FI850323A patent/FI84349C/fi not_active IP Right Cessation
- 1985-01-25 PT PT79890A patent/PT79890B/pt unknown
- 1985-01-25 NO NO850300A patent/NO164025C/no not_active IP Right Cessation
- 1985-01-25 DE DE1993175046 patent/DE19375046I2/de active Active
- 1985-01-25 IL IL74165A patent/IL74165A/xx not_active IP Right Cessation
- 1985-01-25 CA CA000472888A patent/CA1252793A/fr not_active Expired
- 1985-01-25 AU AU38097/85A patent/AU579132B2/en not_active Expired
- 1985-01-25 LU LU88268C patent/LU88268I2/xx unknown
- 1985-01-25 GB GB08501889A patent/GB2153821B/en not_active Expired
- 1985-10-31 ES ES548430A patent/ES8708224A1/es not_active Expired
1986
- 1986-06-16 ES ES556101A patent/ES8801247A1/es not_active Expired
1989
- 1989-02-09 SG SG70/89A patent/SG7089G/en unknown
- 1989-04-20 HK HK331/89A patent/HK33189A/xx not_active IP Right Cessation
- 1989-07-21 CY CY1479A patent/CY1479A/en unknown
1991
- 1991-12-23 SK SK4043-91A patent/SK404391A3/sk unknown
- 1991-12-23 CZ CS914043A patent/CZ404391A3/cs unknown
1994
- 1994-05-31 NL NL940009C patent/NL940009I2/nl unknown
- 1994-11-09 NO NO1994022C patent/NO1994022I1/no unknown

Also Published As

Publication number	Publication date
CH664152A5 (fr)	1988-02-15
CZ404391A3 (en)	1993-04-14
KR850005439A (ko)	1985-08-26
ES8708224A1 (es)	1987-10-01
ES556101A0 (es)	1987-12-16
NL940009I2 (nl)	1999-05-03
AU579132B2 (en)	1988-11-17
ES539852A0 (es)	1986-07-16
NL940009I1 (nl)	1994-07-18
PT79890A (en)	1985-02-01
FR2561244A1 (fr)	1985-09-20
AU3809785A (en)	1985-08-01
PH22672A (en)	1988-11-14
DE3502508C2 (fr)	1990-05-03
GB2153821B (en)	1988-01-20
DK35785D0 (da)	1985-01-25
NO850300L (no)	1985-07-26
GR850219B (fr)	1985-05-23
ES8801247A1 (es)	1987-12-16
ES8609309A1 (es)	1986-07-16
SE460359B (sv)	1989-10-02
ATA20485A (de)	1990-08-15
AT392276B (de)	1991-02-25
IL74165A (en)	1988-11-15
NL8500202A (nl)	1985-08-16
FI84349C (fi)	1991-11-25
FI850323A0 (fi)	1985-01-25
BE901576A (fr)	1985-07-25
DE3502508A1 (de)	1985-08-14
ES548430A0 (es)	1987-10-01
PT79890B (en)	1987-02-03
DK35785A (da)	1985-07-26
SK277923B6 (en)	1995-08-09
FI850323L (fi)	1985-07-26
LU88268I2 (fr)	1994-02-03
SG7089G (en)	1989-06-09
SE8500368D0 (sv)	1985-01-25
KR920003064B1 (ko)	1992-04-13
HK33189A (en)	1989-04-28
IE57809B1 (en)	1993-04-21
IE850187L (en)	1985-07-25
HUT37784A (en)	1986-02-28
NO1994022I1 (no)	1994-11-09
NZ210940A (en)	1989-08-29
LU85743A1 (fr)	1986-08-04
FR2561244B1 (fr)	1988-03-04
DE19375046I2 (de)	2002-10-10
GB2153821A (en)	1985-08-29
HU193592B (en)	1987-11-30
IT1182150B (it)	1987-09-30
CA1252793A (fr)	1989-04-18
FI84349B (fi)	1991-08-15
NL190373C (nl)	1994-02-01
NL190373B (nl)	1993-09-01
CY1479A (en)	1989-07-21
SK404391A3 (en)	1995-08-09
GB8501889D0 (en)	1985-02-27
IT8547600A0 (it)	1985-01-25
SE8500368L (sv)	1985-07-26
NO164025B (no)	1990-05-14
NO164025C (no)	1990-08-22

Publication	Publication Date	Title
DK169521B1 (da)	1994-11-21	3-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne
US5068234A (en)	1991-11-26	3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US4695578A (en)	1987-09-22	1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DK169675B1 (da)	1995-01-09	4-Imidazolylmethyltetrahydrocarbazoloner, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende forbindelserne
DK169922B1 (da)	1995-04-03	Substituerede (imidazol-4-yl)methylpyrido-, og -azepino-, indolonderivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende derivaterne
WO1989010363A1 (fr)	1989-11-02	Composes polycycliques fusionnes, compositions, procedes de fabrication et leurs utilisations comme antagonistes du paf, antihistamines et/ou agents anti-inflammatoires
EP0266899A2 (fr)	1988-05-11	Dérivés d'indole
NO179612B (no)	1996-08-05	Analogifremgangsmåte for fremstilling av 3-arylkarbonyl-1-aminoalkyl-1H-indol-forbindelser
US5563147A (en)	1996-10-08	Serotonerbic tetrahydropyridoindoles
US5849746A (en)	1998-12-15	Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists
DE19707628A1 (de)	1998-08-27	Oxazolidinone
DE3876006T2 (de)	1993-03-25	Keton-derivate.
EP0171037B1 (fr)	1992-06-17	3-Carbonyl-1-aminoalkyl-1H-indoles utilisables comme analgésiques et leur préparation
WO1997032848A1 (fr)	1997-09-12	Composes heterocycliques fusionnes et leurs applications pharmaceutiques
US6211219B1 (en)	2001-04-03	Aminocyclohexane derivatives as 5-HT receptor agonists
US5834482A (en)	1998-11-10	Heterocyclic chemistry
US6127388A (en)	2000-10-03	Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists
JP2776984B2 (ja)	1998-07-16	新規な縮合チアゾール誘導体，その製造法及びその医薬組成物
DK170506B1 (da)	1995-10-02	Pyrido- og azepino-indolforbindelser, fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende dem samt anvendelse af forbindelserne
US6054469A (en)	2000-04-25	Substituted tetrahydropyridine derivatives acting on 5-HT receptors
US5994374A (en)	1999-11-30	Substituted 1-indolylpropyl-4-benzyl-tetrahydropyridine derivatives
US5998416A (en)	1999-12-07	Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT receptor agonists
AU631795C (en)	1994-04-21	Fused polycyclic compounds, compositions, methods of manufacture and their use as PAF antagonists, antihistamines and/or antiinflammatory agents
JPH0378862B2 (fr)	1991-12-17
JPS61210083A (ja)	1986-09-18	複素環式化合物

Legal Events

Date	Code	Title	Description
1994-11-21	B1	Patent granted (law 1993)
1995-03-27	CTFF	Application for supplementary protection certificate (spc) filed	Free format text: CA 1995 00001, 950118
1995-09-11	CTFG	Supplementary protection certificate (spc) issued	Free format text: CA 1995 00001, 950118, EXPIRES: 20050223
2005-02-14	PUP	Patent expired